Target overview
Synonyms
c-MET|MET|hepatocyte growth factor receptor
Emerging Competitive
c-MET / MET
c-MET / MET is flagged as emerging competitive based on 29 active trials across 45 sponsors and 2 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 55
Active trials: 29
Recruiting trials: 17
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 45
Top sponsors: National Cancer Institute (NCI) | GILEAD SCIENCES | City of Hope Medical Center
Tumor types: Multiple Myeloma | Advanced Solid Tumors | Metastatic Colorectal Cancer
Patent-density signal summary
Patent layer
Signal count: 2
Recent signals: 2
Top assignees: AstraZeneca | Zymeworks
Signal types: adc_composition
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 1/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.